Goldman Sachs Group Inc Centessa Pharmaceuticals PLC Put Options Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
Put Options
1 transactions
Others Institutions Holding CNTA
# of Institutions
142Shares Held
124MCall Options Held
163KPut Options Held
816K-
Medicxi Ventures Management (Jersey) LTD20MShares$237 Million75.25% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$118 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$115 Million4.7% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.95MShares$82.5 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X05.92MShares$70.2 Million0.05% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.12B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...